INUSpheresis studies: what research exists, and can you trust it?
The manufacturer lists 19 INUSpheresis publications, mostly small before-and-after blood-marker studies, reviews, case reports and animal or lab work. None is described as randomized or placebo-controlled. They show that substances such as fibrinogen, PFAS and plastic particles can leave the blood, but no study shows better health or longer life.
Nov 17, 2026Updated Nov 18, 20268 min read

The manufacturer of INUSpheresis lists 19 publications dated October 2019 to August 2026. Most are small before-and-after blood-marker studies, literature reviews, case reports, and animal or lab work, and none is described as randomized or placebo-controlled. They show that substances leave the blood. They do not show better health or longer life.
What studies have been published on INUSpheresis, and what did they measure?
The manufacturer lists 19 papers, and almost all of them measured blood markers or what the filters captured. None measured whether people lived longer or had fewer illnesses.
None of the 19 summaries uses the words "randomized," "placebo" or "sham." The only use of "controlled" is a 2026 entry noting that "larger controlled trials are needed to confirm these findings."
The table shows 14 of the 19 papers. Rows follow the manufacturer's summaries, except where a study links to its published paper.
| Study | Design | Subjects | What was measured |
|---|---|---|---|
| Long COVID (2023) | Before and after; no comparison group | 27 people | Blood biomarkers such as fibrinogen |
| PFAS and microplastics (2026) | Before and after two sessions | 34 people | PFAS and plastic particles in blood and removed plasma |
| Microplastics, ME/CFS (2025) | Analysis of removed plasma | 21 people | "MNP-like" particles in filtered-out fluid |
| MENA cohort (2025) | Before and after | 24 men | Plasma analyses |
| Proteomics (2025) | Before and after | 12 people | Blood proteins |
| Toxin case series (2025) | Retrospective review | Not given | What the filters captured |
| Inflammation indices (2025) | Retrospective, single center | Not given | Inflammation indices in lipid patients |
| Bioreactor (2026) | Animal and lab | Sheep, rabbits, rats; 20 tumor cell lines | No human data |
| Dogs (2025) | Ex vivo study plus retrospective report | Canine blood; 3 dogs, 5 treatments | Procedure performance |
| Alzheimer's (2019) | Described as reporting "early findings" | Not given | Not given |
| Reviews (2020, 2021, 2024) | Literature reviews | None | Prior research |
| Water structure (2022) | Case study | Not given | Near-infrared signals in hand tissue |
The other five listed papers are a 2026 study of plasma separation efficiency, a 2020 lipid study in patients with Lyme disease, a 2022 precision-medicine proteomics study, a 2022 case study of particles examined by electron microscopy (FE-SEM), and a 2024 perspective on multimodal treatment of long COVID.
What did the long COVID INUSpheresis study find?
Blood markers fell after treatment in 27 long COVID patients who showed clinical improvement. The study had no comparison group, and its authors describe the result as only an association and not causality.
The paper in Molecular Psychiatry describes a cohort of 27 patients with Long-Covid treated with INUSpheresis using the TKM58 filter. Patients were treated twice, 3 weeks apart. Each session lasted about 114 minutes and included 8,000 units of heparin, a blood thinner. The analysis covered 27 patients who showed clinical improvement, and the authors report a 70% reduction in fibrinogen, a clotting protein.
The authors state the limits plainly. The study was not a randomized controlled trial with sham procedures. They note that heparin, which promotes tissue perfusion, could explain the benefit. They also point to the lack of hard endpoints for measuring long COVID symptoms objectively.
The manufacturer's summary says patients experienced improvements in energy levels, cognitive function, and overall well-being. That description goes further than the paper, which did not test treatment against an inactive comparison.
Standard plasma exchange has had that test. In a 2025 trial, fifty people with post-COVID condition were randomly assigned to six sessions of real or sham plasma exchange. The treatment did not lead to any discernible improvement. That trial did not test INUSpheresis. It does show why sham controls matter. More detail is in the piece on the randomized long COVID plasma exchange trial.
Does INUSpheresis remove microplastics, PFAS or heavy metals?
Early studies show these substances can be measured leaving the blood or collecting in the filters. No study shows that removing them improves health.
The 2026 Brain Health paper reports decreases in both PFAS and micro- and nanoplastic levels after double filtration, "although responses varied across individuals and analytes." The authors add that larger, well-designed clinical trials are needed.
The 2025 microplastics paper analyzed the filtered-out fluid for "MNP-like" particles. The manufacturer calls this the first evidence that INUSpheresis has the potential to remove MNP-like particles. For the 2025 toxin case series, it goes further, describing the work as demonstrating that DFPP is effective in removing heavy metals, volatile organic compounds, and organic pollutants. That series was retrospective and measured what the filters held, not any change in health.
A separate study of standard plasma exchange adds a caution. Researchers measured microplastics in 114 patients before and after 174 standard plasma exchange procedures and found levels fell. At low starting levels, the reduction was obscured by leaching of microplastics back into the circulation from the plastic tubing set. Most of those authors are affiliated with Circulate Health.
A 2026 narrative review, whose author declares no financial relationships, cites a study in which double filtration achieved significant clearance of serum PFOS, a common PFAS chemical. It concludes only that plasma exchange may be a beneficial intervention.
Who writes INUSpheresis research, and what ties do authors disclose?
One research group wrote most of the papers, and the 2026 paper discloses that some of its authors advise or work for the Ayus Medical Group.
The author lists on the manufacturer's page show Stefan R. Bornstein as a co-author on 15 of the 19 papers. Yannick P. Kok, Philip Mavberg or both appear on 7, including the MENA, proteomics, toxin, bioreactor and Brain Health papers.
The 2026 Brain Health paper discloses that SRB is on the advisory board of Ayus Medical Group and several other companies, and that "YPK and PM work at the Ayus Medical Group." Kok is listed at Ayus Laboratories AG and Mavberg at Ayus Medical Basel. Bornstein is listed at TU Dresden, King's College London and University Hospital Zurich.
Industry ties are common in apheresis research. The Alzheimer's plasma exchange trial lists six authors as full-time Grifols employees, and an ageing trial discloses that three authors are members of Circulate Inc. Both were controlled trials, though the ageing trial assigned groups by entry date. Company ties weigh more heavily when no independent group has repeated the work.
How does INUSpheresis evidence compare with standard plasma exchange?
Standard plasma exchange (TPE) has formal disease-by-disease grading and several controlled trials, with mixed results. INUSpheresis has neither for longevity, detox or long COVID.
The procedures differ. TPE removes your plasma and replaces it with a substitute fluid. INUSpheresis, the manufacturer explains, is a double-membrane filtration system: one module separates blood cells from plasma, and a second filter removes lipids or inflammatory substances before your own plasma is returned. This approach is called double filtration plasmapheresis (DFPP). A canine study by veterinary researchers, listed by the manufacturer, describes DFPP as a semi-selective plasma-exchange modality that spared albumin and reduced the need for substitution fluids in canine blood at 1.5 plasma volumes. Research on one procedure does not automatically apply to the other. See how INUSpheresis differs from plasma exchange.
Apheresis is the general family of procedures that separate and process blood outside the body. The American Society for Apheresis grades its uses in guidelines whose tenth edition contains 93 fact sheets and 183 graded and categorized indications. The abstract does not mention INUSpheresis, longevity or detox.
TPE trials show what controlled evidence looks like:
- Alzheimer's (AMBAR): 347 patients were randomized. A daily-living measure showed 52% less decline (P = .03), with no changes in mild-AD patients.
- Long COVID: sham-controlled, with no discernible improvement.
- Ageing: 42 participants, with 15 epigenetic clocks showing rejuvenation compared to placebo. A clock change is a biomarker, not proof of longer life.
Evidence status at a glance
- Established: apheresis has formal guideline grading, and TPE has randomized trials in some conditions. None of this transfers automatically to INUSpheresis.
- Emerging, biomarker-level only: falling blood markers in a small uncontrolled long COVID cohort, variable drops in PFAS and plastic particles, and particles found in filtered plasma.
- Unproven: claims that INUSpheresis improves health, reverses ageing, or treats long COVID, Alzheimer's or cancer. The manufacturer says a bioreactor "will be integrated" in future and "can therefore be used as therapy for cancer forms, autoimmune diseases with antibodies, Alzheimer disease with tau proteins, and others." So far it has been tested only in animals and 20 tumor cell lines.
What should you ask a clinic that says INUSpheresis is proven?
Ask for the specific study, its design, the outcome it measured and who funded it. Then ask about your own risks and the full price, in writing.
- Which paper supports the claim for my goal, and was it randomized or sham-controlled?
- Did it measure symptoms, function or survival, or only blood markers?
- Do the authors work for or advise the manufacturer?
- How will my medications be handled? The American College of Rheumatology notes that plasma exchange can remove some medications. Ask whether the same applies to filtration.
- What side effects do you see, and how much heparin do you use? Patient information on TPE says people may feel cold, nauseated, or experience mild tingling.
- What is the total cost of the course?
Northvane's clinic listings, checked 18 November 2026, show Biologicum Hamburg at EUR 2,900 per INUSpheresis session and ELLANN Health at EUR 5,400 to 5,700 for a two-treatment course. Confirm the total cost of any course in writing before you book, and compare published INUSpheresis prices. A physician who knows your history is the right person to weigh the answers with you.
Common questions
Does the "34,000 studies" figure mean INUSpheresis is well studied?
No. The manufacturer's page says apheresis has been "studied in over 34,000 studies (PubMed, March 2026)." That figure covers the whole apheresis field, including standard plasma exchange and other procedures. It is not a count of INUSpheresis trials. The same page lists 19 INUSpheresis publications, none described as randomized or placebo-controlled.
Is INUSpheresis the same as young-donor plasma infusion?
No. INUSpheresis filters your own plasma and returns it to you. Young-donor plasma infusion gives a person plasma from younger donors, and the FDA warned in 2019 that there is no proven clinical benefit of plasma from young donors for ageing or memory loss. Evidence about one practice tells you nothing about the other.
Sources11 cited
- [1]Scientific Studies on Inuspheresis® | blood plasma purification · inuspheresis.com
- [2]Long COVID (2023) · nature.com
- [3]PFAS and microplastics (2026) · doi.org
- [4]Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial - Nature Communications · doi.org
- [5]Can Plasma Exchange Be Used to Lower the Circulating Burden of Microplastics in Human Patients? · doi.org
- [6]Role of Therapeutic Plasma Exchange in Accelerating the Clearance of Perfluoroalkyl and Polyfluoroalkyl Substances. · doi.org
- [7]A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. · doi.org
- [8]three authors are members of Circulate Inc. · doi.org
- [9]93 fact sheets and 183 graded and categorized indications · doi.org
- [10]Plasma Exchange (Plasmapheresis) | American College of Rheumatology · rheumatology.org
- [11]Important Information about Young Donor Plasma Infusions for Profit | FDA · fda.gov
For information, not medical advice. Suggest a correction · Editorial policy


